You can find more information about Ca2+-pump using the following links:

PFID

PFID Old

Formal Annotation

PlasmoDB

TDR Targets

Subcellular Localization

Affecting Drugs

Drug Name

PubMed Articles (year of publication)

PF3D7_0106300

PFA0310c

calcium-transporting ATPase, ATP6

PlasmoDB

TDR

(1E,4E)-1,5-bis(4-methoxyphenyl)penta-1,4-dien-3-one	Design, in silico and in vitro evaluation of curcumin analogues against Plasmodium falciparum
(1E,4E)-1,5-bis(4-methylphenyl)penta-1,4-dien-3- one	Design, in silico and in vitro evaluation of curcumin analogues against Plasmodium falciparum
(1R,3R,5aS,5bR,9S,11aR)-3-((3-(4-(3-aminopropyl)piperazin-1-yl)propyl)carbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysen-9-yl acetate	SERCA plays a crucial role in the toxicity of a betulinic acid derivative with potential antimalarial activity
(3R,5aalpha,8aalpha,12aR)-10beta-(6-Oxotetrahydro-2H-pyran-2-yl)decahydro-3,6alpha,9beta-trimethyl-3beta,12alpha-epoxypyrano[4,3-j]-1,2-benzodioxepin	Mechanism of artemisinin resistance for malaria PfATP6 L263 mutations and discovering potential antimalarials: An integrated computational approach
(4S,5E,8S,9E,11S,13E,15E,18R)-4-(((2R,3R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-methoxytetrahydro-2H-pyran-2-yl)oxy)-8-methoxy-9,11-dimethyl-18-((1Z,4E)-2-methylhexa-1,4-dien-1-yl)oxacyclooctadeca-5,9,13,15-tetraen-2-one	Design, synthesis and anti-malarial activities of synthetic analogs of biselyngbyolide B, a Ca 2+ pump inhibitor from marine cyanobacteria
(E)-1-(3-phenyl-1-(p-tolylamino)allyl)urea	Octopus: a platform for the virtual high-throughput screening of a pool of compounds against a set of molecular targets
(E)-1,3- bis(4-hydroxylphenyl)prop-2-en-1-one	Design, in silico and in vitro evaluation of curcumin analogues against Plasmodium falciparum
1,2,4,5-tetraoxane	Docking studies of structurally diverse antimalarial drugs targeting PfATP6: no correlation between in silico binding affinity and in vitro antimalarial activity
1,2,4-tri-oxane	Docking studies of structurally diverse antimalarial drugs targeting PfATP6: no correlation between in silico binding affinity and in vitro antimalarial activity
1,2,4-trioxolane	Docking studies of structurally diverse antimalarial drugs targeting PfATP6: no correlation between in silico binding affinity and in vitro antimalarial activity
1-benzofuran-2-yl-[4-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl]methanone	Structure-based drug design studies of the interactions of ent-kaurane diterpenes derived from Wedelia paludosa with the Plasmodium falciparum sarco/endoplasmic reticulum Ca²?-ATPase PfATP6
2,5-di(tert-butyl)-1,4-benzohydroquinone	Purified E255L mutant SERCA1a and purified PfATP6 are sensitive to SERCA-type inhibitors but insensitive to artemisinins Antimalarial screening via large-scale purification of Plasmodium falciparum Ca2+-ATPase 6 and in vitro studies
4-(3-(3-((4-butylpiperazin-1-yl)(imino)methyl)phenyl)ureido)-N-(4-sulfamoylbenzyl) benzenesulfonamide	SC83288 is a clinical development candidate for the treatment of severe malaria
AGN-PC-036KA3	Structure-based drug design studies of the interactions of ent-kaurane diterpenes derived from Wedelia paludosa with the Plasmodium falciparum sarco/endoplasmic reticulum Ca²?-ATPase PfATP6
Artemether	Identification of an antimalarial synthetic trioxolane drug development candidate Lack of association of the S769N mutation in Plasmodium falciparum SERCA (PfATP6) with resistance to artemisinins
Artemisinin	Identification of an antimalarial synthetic trioxolane drug development candidate A single amino acid residue can determine the sensitivity of SERCAs to artemisinins The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data
artemisinin dimer	Selective Inhibition of Plasmodium falciparum ATPase 6 by Artemisinins and Identification of New Classes of Inhibitors after Expression in Yeast
Artemisone	A single amino acid residue can determine the sensitivity of SERCAs to artemisinins Docking studies of structurally diverse antimalarial drugs targeting PfATP6: no correlation between in silico binding affinity and in vitro antimalarial activity
Artesunate	Identification of an antimalarial synthetic trioxolane drug development candidate Lack of association of the S769N mutation in Plasmodium falciparum SERCA (PfATP6) with resistance to artemisinins
calmidazolium	Calmidazolium evokes high calcium fluctuations in Plasmodium falciparum
Chembl2172226	Combined receptor-based and ligand-based approach to delineate the mode of binding of guaianolide-endoperoxides to PfATP6
Chloroquine	Effect of chloroquine phosphate and toxic concentrations of lead acetate on Ca2+-ATPase activity in isolates and clones of Plasmodium falciparum
CID 10625452	Mechanism of artemisinin resistance for malaria PfATP6 L263 mutations and discovering potential antimalarials: An integrated computational approach
Crystal structure, suggested target	Combined receptor-based and ligand-based approach to delineate the mode of binding of guaianolide-endoperoxides to PfATP6
Curcumin	Interactions of curcumin with the PfATP6 model and the implications for its antimalarial mechanism Inhibition of P. falciparum PFATP6 by curcumin and its derivatives: a bioinformatic study
Cyclopiazonic acid	Purified E255L mutant SERCA1a and purified PfATP6 are sensitive to SERCA-type inhibitors but insensitive to artemisinins Antimalarial screening via large-scale purification of Plasmodium falciparum Ca2+-ATPase 6 and in vitro studies
Dihydroartemisinin	Docking studies of structurally diverse antimalarial drugs targeting PfATP6: no correlation between in silico binding affinity and in vitro antimalarial activity Lack of association of the S769N mutation in Plasmodium falciparum SERCA (PfATP6) with resistance to artemisinins
ergosterol5,8-endoperoxide	Steroids from Diplazium esculentum: Antiplasmodial activity and molecular docking studies to investigate their binding modes
Guaianolide	Combined receptor-based and ligand-based approach to delineate the mode of binding of guaianolide-endoperoxides to PfATP6
Iron + artemisinin	A plausible mechanism for the antimalarial activity of artemisinin: A computational approach
Lead diacetate	Effect of chloroquine phosphate and toxic concentrations of lead acetate on Ca2+-ATPase activity in isolates and clones of Plasmodium falciparum
methyl (2R,3'R,6a'R,6b'R,7a'R)-3',6a'-dimethyldecahydro-9'H,11'H-spiro[oxirane-2,10'-[9,11a]methanonaphtho[1',2':1,7]cyclohepta[1,2-b]oxirene]-3'-carboxylate	Structure-based drug design studies of the interactions of ent-kaurane diterpenes derived from Wedelia paludosa with the Plasmodium falciparum sarco/endoplasmic reticulum Ca²?-ATPase PfATP6
methyl (3R,6aR,6bR,7aR,10S)-10-hydroxy-10-(hydroxymethyl)-3,6a-dimethyldodecahydro-9H-9,11a-methanonaphtho[1',2':1,7]cyclohepta[1,2-b]oxirene-3-carboxylate	Structure-based drug design studies of the interactions of ent-kaurane diterpenes derived from Wedelia paludosa with the Plasmodium falciparum sarco/endoplasmic reticulum Ca²?-ATPase PfATP6
methyl (4R,8S,11bS)-8-(hexahydropyrimidin-2-yl)-4,11b-dimethyltetradecahydro-6a,9-methanocyclohepta[a]naphthalene-4-carboxylate	Structure-based drug design studies of the interactions of ent-kaurane diterpenes derived from Wedelia paludosa with the Plasmodium falciparum sarco/endoplasmic reticulum Ca²?-ATPase PfATP6
methyl 4-(imino(3-(3-(4-(N-(4-sulfamoylbenzyl)sulfamoyl)phenyl)ureido) phenyl)methyl) piperazine-1-carboxylate	SC83288 is a clinical development candidate for the treatment of severe malaria
N-{3-[4-(3-aminopropyl)piperazinyl]propyl}-3-Ohexanoylbetulinamide	Identification of an antimalarial synthetic trioxolane drug development candidate
Nsc 95397	Antimalarial screening via large-scale purification of Plasmodium falciparum Ca2+-ATPase 6 and in vitro studies
Oz277	Identification of an antimalarial synthetic trioxolane drug development candidate
Rbx-11160	Mechanism of antimalarial action of the synthetic trioxolane RBX11160 (OZ277)
Rh5 antibody	Characterization of the differences in the cyclopiazonic acid binding mode to mammalian and P. Falciparum Ca2+ pumps: a computational study
Simulated noncompetitive inhibitors	The binding modes and binding affinities of artemisinin derivatives with Plasmodium falciparum Ca2+-ATPase (PfATP6)
Thaperoxide	Design, synthesis, and development of novel guaianolide-endoperoxides as potential antimalarial agents
Thapsigargin	Plasmodium falciparum malaria parasites display a THG-sensitive Ca2+ pool Purified E255L mutant SERCA1a and purified PfATP6 are sensitive to SERCA-type inhibitors but insensitive to artemisinins Design, synthesis, and development of novel guaianolide-endoperoxides as potential antimalarial agents Antimalarial screening via large-scale purification of Plasmodium falciparum Ca2+-ATPase 6 and in vitro studies Calmidazolium evokes high calcium fluctuations in Plasmodium falciparum Fragment Molecular Orbital Study of the Interaction between Sarco/Endoplasmic Reticulum Ca 2+-ATPase and its Inhibitor Thapsigargin toward Anti-Malarial Development

PF3D7_1211900

PFL0590c

non-SERCA-type Ca2+ -transporting P-ATPase, ATP4

PlasmoDB

TDR

(+)-SJ733	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
(1R,3'S,6'R,8a'R)-6''-amino-3-(cyanomethyl)-3'-(hydroxymethyl)-2'',5'-dioxo-2,2',3,3',8',8a'-hexahydro-5'H,7'H-dispiro[indene-1,1'-indolizine-6',3''-indoline]-3-carbonitrile	Natural Product Inspired Novel Indole based Chiral Scaffold Kills Human Malaria Parasites via Ionic Imbalance Mediated Cell Death
(2S,3S,4R)-1-(cyclopentanecarbonyl)-4-(hydroxymethyl)-3-[2-(4-methoxyphenyl)phenyl]azetidine-2-carbonitrile	Diversity-oriented synthesis yields novel multistage antimalarial inhibitors
(3aR)-8-chloro-N-(5-chloropyridin-3-yl)-4-methyl-1,5-dioxo-1,2,3,4,5,9b-hexahydro-3aH-cyclopenta[c]isoquinoline-3a-carboxamide	Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials Targeting PfATP4
(3S,4S)-N-(3-Cyano-4-fluorophenyl)-1-oxo-3-(3-pyridinyl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydro-4-isoquinolinecarboxamide	Using in Vitro Evolution and Whole Genome Analysis To Discover Next Generation Targets for Antimalarial Drug Discovery
(8R,9S,10S)-10-[(dimethylamino)methyl]-N-(4-methoxyphenyl)-9-[4-(2-phenylethynyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide	Diversity-oriented synthesis yields novel multistage antimalarial inhibitors
(E)-3-(furan-2-ylmethyl)-8-methoxy-6-(prop-1-en-1-yl)-3,4-dihydro-2H-benzo[e][1,3]oxazine	Benzoxazine derivatives of phytophenols show anti-plasmodial activity via sodium homeostasis disruption
4-cyano-3-methylisoquinoline	A 4-cyano-3-methylisoquinoline inhibitor of Plasmodium falciparum growth targets the sodium efflux pump PfATP4
5',7-Dichloro-6-fluoro-3-methyl-2,3,4,9-tetrahydrospiro[β-carboline-1,3'-indol]-2'-ol	Using in Vitro Evolution and Whole Genome Analysis To Discover Next Generation Targets for Antimalarial Drug Discovery
5',7-Dichloro-6-fluoro-3-methyl-2,3,4,9-tetrahydrospiro[β-carboline-1,3'-indol]-2'-ol [	Using in Vitro Evolution and Whole Genome Analysis To Discover Next Generation Targets for Antimalarial Drug Discovery
5-bromo-3'-(4-chlorophenyl)-5′-phenyl-3′H-spiro[indoline-3,2'- [1,3,4]oxadiazol]-2-one	Discovery of spirooxadiazoline oxindoles with dual-stage antimalarial activity
cipargamin	Biochemical characterization and chemical inhibition of PfATP4-associated Na +-ATPase activity in Plasmodium falciparum membranes A G358S mutation in the Plasmodium falciparum Na+ pump PfATP4 confers clinically-relevant resistance to cipargamin
C-linked phenyl butenonyl c-glycosides with ureidyl, thioureidyl, and sulfonamidyl moieties	Diverse chemotypes disrupt ion homeostasis in the Malaria parasite
Cyclopiazonic acid	Expression and functional characterization of a Plasmodium falciparum Ca2+-ATPase (PfATP4) belonging to a subclass unique to apicomplexan organisms
cyclosporin A	New leads for drug repurposing against malaria
Essentiality, suggested target	Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum
Gnf-pf4492	Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials
KAE609	A Basis for Rapid Clearance of Circulating Ring-Stage Malaria Parasites by the Spiroindolone KAE609 A high-sensitivity HPLC assay for measuring intracellular Na(+) and K(+) and its application to Plasmodium falciparum infected erythrocytes Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways Cell Swelling Induced by the Antimalarial KAE609 (Cipargamin) and Other PfATP4-Associated Antimalarials
KAF246	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
Mls000116597	Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials
MMV000642	The relative rate of kill of the MMV Malaria Box compounds provides links to the mode of antimalarial action and highlights scaffolds of medicinal chemistry interest
MMV000653	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
MMV000662	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways Biochemical characterization and chemical inhibition of PfATP4-associated Na +-ATPase activity in Plasmodium falciparum membranes
MMV000848	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
MMV006427	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
MMV006429	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
MMV007617	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
MMV007978	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
MMV009063	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
MMV011567	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
MMV019017	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
MMV020660	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
MMV396633	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
MMV396715	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
MMV396719	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
MMV396749	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
MMV665796	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
MMV665800	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
MMV665803	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
MMV665826	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
MMV665857	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
MMV665878	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
MMV665890	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
MMV665918	Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways
N-(4-(4-chloro-2-fluorophenyl)-1,3-dimethyl-1H-pyrazol5-yl)-2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)acetamid	Using in Vitro Evolution and Whole Genome Analysis To Discover Next Generation Targets for Antimalarial Drug Discovery
Naproxen	(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium
NITD139	A high-sensitivity HPLC assay for measuring intracellular Na(+) and K(+) and its application to Plasmodium falciparum infected erythrocytes
Nitd246	A high-sensitivity HPLC assay for measuring intracellular Na(+) and K(+) and its application to Plasmodium falciparum infected erythrocytes
Nitd609	Spiroindolones, a potent compound class for the treatment of malaria Antimalarial drug discovery - approaches and progress towards new medicines Antiapicoplast and gametocytocidal screening to identify the mechanisms of action of compounds within the malaria box Spiroindolone NITD609 is a novel antimalarial drug that targets the P-type ATPase PfATP4
Omeprazole	New leads for drug repurposing against malaria
PA21A092	Metabolic responses in blood-stage malaria parasites associated with increased and decreased sensitivity to PfATP4 inhibitors
SJ733	Plasmid-free CRISPR/Cas9 genome editing in Plasmodium falciparum confirms mutations conferring resistance to the dihydroisoquinolone clinical candidate SJ733
Spiroindolone	Spiroindolones, a potent compound class for the treatment of malaria Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials Na+ extrusion imposes an acid load on the intraerythrocytic malaria parasite
Spirotetrahydro-β–carbolines	Spiroindolones, a potent compound class for the treatment of malaria
Vanadate	Expression and functional characterization of a Plasmodium falciparum Ca2+-ATPase (PfATP4) belonging to a subclass unique to apicomplexan organisms

Expasy - NiceZime View
Brenda - The Comprehensive Enzyme Information System